Last reviewed · How we verify
BAT2306
BAT2306 is a bispecific antibody that simultaneously engages two immune checkpoints to enhance anti-tumor T cell responses.
BAT2306 is a bispecific antibody that simultaneously engages two immune checkpoints to enhance anti-tumor T cell responses. Used for Advanced or metastatic solid tumors (Phase 3 development).
At a glance
| Generic name | BAT2306 |
|---|---|
| Also known as | Recombinant human monoclonal antibody against IL-17A |
| Sponsor | Bio-Thera Solutions |
| Drug class | Bispecific checkpoint inhibitor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
BAT2306 functions as a bispecific monoclonal antibody designed to target multiple immune regulatory pathways. By engaging dual checkpoint mechanisms, it aims to overcome immune evasion and promote robust T cell activation and proliferation against tumor cells. This dual-targeting approach is intended to improve efficacy compared to single-checkpoint inhibitors.
Approved indications
- Advanced or metastatic solid tumors (Phase 3 development)
Common side effects
Key clinical trials
- Assessment on Efficacy and Safety of BAT2306 and Cosentyx® in Plaque Psoriasis Patients (PHASE3)
- Comparative Study to Evaluate the Pharmacokinetics of BAT2306 vs Cosentyx® in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BAT2306 CI brief — competitive landscape report
- BAT2306 updates RSS · CI watch RSS
- Bio-Thera Solutions portfolio CI